{"documentId":"1N5CompetitorMonitorTracker_nop432QrStUvWxYz12AbCd","title":"Competitor Monitoring Tracker — Zenvara Class","revisionId":"rev-1N5Competito","body":{"content":[{"sectionBreak":{"sectionStyle":{"columnSeparatorStyle":"NONE","contentDirection":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":69,"textRun":{"content":"Competitor Monitoring Tracker — Zenvara Class (NSCLC Immunotherapy)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"TITLE","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":155,"textRun":{"content":"Maintained by Jordan Patel, CI Analyst. Updated weekly or on event-trigger. Distribution: VP Commercial, Medical Affairs Director, Launch Lead, MSL Lead.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":10,"textRun":{"content":"Overview\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":376,"textRun":{"content":"The tracker monitors 6 directly-competitive assets in development across 5 sponsor companies, plus 4 watch-list assets in adjacent indications that could pivot into NSCLC. The most material change this week (May 14, 2026) is the CheckMate-X readout from BMS, which missed primary PFS in 2L NSCLC and substantially de-risks the competitive landscape for our ZENITH-2 program.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":37,"textRun":{"content":"Active direct competitors (Phase 3)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":220,"textRun":{"content":"BMS CheckMate-X (nivolumab + relatlimab combination) — 2L NSCLC. Phase 3 enrolled. STATUS UPDATE 2026-05-14: missed primary PFS endpoint (HR 0.91, p=0.18). BMS unlikely to pursue 2L label. Threat level: LOW (was HIGH).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":187,"textRun":{"content":"Roche IMpower-YY (atezolizumab + bevacizumab) — 1L NSCLC PD-L1 high. Phase 3, readout expected Q3 2026. Threat level: MEDIUM. ASCO 2026 presentation: full data, Plenary Tuesday session.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":251,"textRun":{"content":"AstraZeneca PACIFIC-ZZZ (durvalumab + new agent) — locally advanced NSCLC post-CRT. Phase 3, completed enrollment April 2025. Readout expected H1 2027. Threat level: MEDIUM (different patient population but could pivot to 1L metastatic if positive).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":162,"textRun":{"content":"Merck KEYNOTE-WWW (pembrolizumab + new oral agent) — 1L NSCLC PD-L1 high. Phase 3, enrolling. Threat level: MEDIUM-HIGH (head-to-head positioning with Zenvara).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":186,"textRun":{"content":"Novartis NIVA-001 (novel checkpoint inhibitor) — 1L NSCLC. Phase 3, completed enrollment Q1 2026. Readout expected mid-2027. Threat level: LOW-MEDIUM (limited supporting Phase 2 data).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":156,"textRun":{"content":"AbbVie AGN-202 (anti-CTLA-4 + anti-PD-L1 combination) — 1L NSCLC. Phase 3 enrollment started 2026-04-18. Threat level: WATCH (early-stage; readout 2028+).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":21,"textRun":{"content":"Adjacent watch list\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":129,"textRun":{"content":"Daiichi Sankyo DESTINY-Lung-XX (trastuzumab deruxtecan) — HER2-mutant NSCLC. Different biomarker population. Threat level: LOW.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":88,"textRun":{"content":"Gilead Trodelvy + IO combinations — Phase 2 in NSCLC. Threat level: LOW (early-stage).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":78,"textRun":{"content":"BMS-Exelixis Cabometyx + nivolumab — 1L NSCLC. Phase 2. Threat level: WATCH.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":161,"textRun":{"content":"Sanofi/Regeneron Libtayo (cemiplimab) — 1L NSCLC PD-L1 high. Phase 3 mature data, Phase 4 ongoing. Threat level: LOW (already in market with limited 1L share).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":42,"textRun":{"content":"Recent material events (rolling 90 days)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":100,"textRun":{"content":"May 14, 2026: BMS CheckMate-X readout missed primary PFS. See ASCO 2026 Readout (1L9…) for detail.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":201,"textRun":{"content":"April 28, 2026: BMS held investor briefing post-Q1 earnings; CFO acknowledged 'mixed Phase 3 readouts' in their oncology pipeline. Signal: BMS may pivot capital allocation away from late-stage NSCLC.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":222,"textRun":{"content":"April 18, 2026: AbbVie AGN-202 Phase 3 enrollment began. AbbVie press release positioned the program as 'differentiated combination approach.' Investors and analysts received cautiously. Site activation in US, EU, China.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":169,"textRun":{"content":"March 22, 2026: Roche presented IMpower-YY interim safety data at ELCC; no efficacy data. Safety profile consistent with prior atezolizumab + bevacizumab combinations.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":161,"textRun":{"content":"March 8, 2026: Merck published KEYNOTE-WWW Phase 2b data in Lancet Oncology. ORR 52%, mPFS 11.2 months. Strong Phase 2b signal positions the Phase 3 favorably.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":109,"textRun":{"content":"February 14, 2026: AstraZeneca PACIFIC-ZZZ enrollment milestone announcement. On track for H1 2027 readout.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":103,"textRun":{"content":"January 30, 2026: Novartis NIVA-001 Phase 2 update at virtual investor event. Mixed signal; CIs wide.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":49,"textRun":{"content":"Competitive landscape map (1L NSCLC PD-L1 high)\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":285,"textRun":{"content":"Currently in market: pembrolizumab (Merck, KEYNOTE-189, KEYNOTE-024 — original SoC, broad indication). Atezolizumab (Roche, IMpower130 in adenocarcinoma). Zenvara (zenvalimab — our product, ZENITH-1 positive). Cemiplimab (Sanofi/Regeneron, EMPOWER-Lung 1 — modest commercial uptake).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":87,"textRun":{"content":"Approaching market: Roche IMpower-YY readout Q3 2026; Merck KEYNOTE-WWW readout 2027.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":44,"textRun":{"content":"Watch: Novartis NIVA-001 readout mid-2027.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":14,"textRun":{"content":"Implications\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":165,"textRun":{"content":"Near-term (next 6 months): CheckMate-X failure relieves competitive pressure in 2L NSCLC. Less defensive messaging required; focus on ZENITH-2 forward positioning.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":207,"textRun":{"content":"Mid-term (6-18 months): IMpower-YY Q3 2026 readout is the next major competitive event. If positive, Roche becomes a real 1L PD-L1-high competitor; if negative, Zenvara consolidates 1L positioning further.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":288,"textRun":{"content":"Long-term (18-36 months): KEYNOTE-WWW readout (2027) is the head-to-head with the current SoC. If positive, Merck differentiation strengthens against Zenvara; if negative, Zenvara has clearer 1L positioning. KEYNOTE-WWW Phase 2b data suggests a positive readout is more likely than not.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":210,"textRun":{"content":"AbbVie AGN-202 is the only late-stage development asset entering the space in 2026; readout 2028+. Long enough horizon that strategic response should be on the indication-expansion side rather than defensive.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":20,"textRun":{"content":"Monitoring sources\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":273,"textRun":{"content":"Conference abstract feeds (ASCO Meeting Library, ESMO ePoster system, ELCC), competitor earnings calls (quarterly), CT.gov enrollment data (monthly review), trade publications (FierceBiotech, EndPoints, BioCentury), KOL networks (MSL channel + sponsored advisory boards).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":162,"textRun":{"content":"Automated alerts configured for: CT.gov status changes on tracked trials, sponsor IR materials on competitor programs, FDA approval announcements in indication.\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":18,"textRun":{"content":"Cross-references\n","textStyle":{"bold":true}}}],"paragraphStyle":{"namedStyleType":"HEADING_2","direction":"LEFT_TO_RIGHT"}}},{"paragraph":{"elements":[{"startIndex":1,"endIndex":104,"textRun":{"content":"ASCO 2026 Readout (1L9…), KOL Advisory Board Apr 2026 Synthesis (1M2…), 2026 Congress Calendar (1O8…).\n","textStyle":{}}}],"paragraphStyle":{"namedStyleType":"NORMAL_TEXT","direction":"LEFT_TO_RIGHT"}}}]},"documentStyle":{"pageNumberStart":1,"marginTop":{"magnitude":72,"unit":"PT"},"marginBottom":{"magnitude":72,"unit":"PT"},"marginLeft":{"magnitude":72,"unit":"PT"},"marginRight":{"magnitude":72,"unit":"PT"},"pageSize":{"height":{"magnitude":792,"unit":"PT"},"width":{"magnitude":612,"unit":"PT"}}},"namedStyles":{"styles":[{"namedStyleType":"NORMAL_TEXT","textStyle":{"fontSize":{"magnitude":11,"unit":"PT"}}},{"namedStyleType":"TITLE","textStyle":{"fontSize":{"magnitude":26,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_1","textStyle":{"fontSize":{"magnitude":20,"unit":"PT"},"bold":true}},{"namedStyleType":"HEADING_2","textStyle":{"fontSize":{"magnitude":16,"unit":"PT"},"bold":true}}]},"lists":{},"inlineObjects":{},"headers":{},"footers":{},"footnotes":{},"suggestionsViewMode":"DEFAULT_FOR_CURRENT_ACCESS"}